Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2716887 | 1.00 | CTSS (0.77) | CTSSTRPV1 | |
| SCHEMBL2682772 | 0.91 | CTSS (0.77) | CTSSTRPV1 | |
| SCHEMBL2717741 | 0.91 | CTSS (0.77) | CTSSTRPV1 | |
| SCHEMBL3056138 | 0.90 | CTSS (0.80) | CTSS | |
| SCHEMBL2719518 | 0.89 | CTSS (0.62) | CTSSTRPV1 | |
| SCHEMBL2682621 | 0.89 | CTSS (0.62) | CTSSTRPV1 | |
| SCHEMBL2719521 | 0.89 | CTSS (0.62) | CTSSTRPV1 | |
| SCHEMBL4740893 | 0.87 | CTSS (0.79) | CTSSTRPV1 | |
| SCHEMBL2717163 | 0.87 | CTSS (1.00) | CTSS | |
| SCHEMBL2685202 | 0.87 | CTSS (1.00) | CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635562-B1 | PYRROLIDINE DERIVATIVES USED AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-09-03 | — | — | EP | disclosed |
| EP-2635562-B1 | PYRROLIDINE DERIVATIVES USED AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-09-03 | — | — | EP | disclosed |
| EP-2635562-A1 | PYRROLIDINE DERIVATIVES USED AS CATHEPSIN INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-11 | — | — | EP | disclosed |
| US-8524710-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524710-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524710-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| WO-2012059507-A1 | PYRROLIDINE DERIVATIVES USED AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012059507-A1 | PYRROLIDINE DERIVATIVES USED AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
| US-20120115843-A1 | NOVEL PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-05-10 | — | — | US | disclosed |
| US-20120115843-A1 | NOVEL PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-05-10 | — | — | US | disclosed |
| US-20120115843-A1 | NOVEL PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115843-A1 | NOVEL PYRROLIDINE DERIVATIVES | CTSD, CTSV, CTSS | CTSS 3/4885TRPV1 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.